All In Biotech

Drug Trial Radar · NCT00264901

Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes

Impact of a Self-Adjusted Titration Guideline in Subjects With Type 2 Diabetes Mellitus: A Treat-to-Target of the Efficacy and Safety of Levemir® (Insulin Detemir [rDNA Origin] Injection) (PREDICTIVE™ 303)

Last checked: Nov 20, 2026Latest source record: Jan 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 5,652 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,652

Actual

Start

Oct 2005

Primary completion

Nov 2006

Study completion Nov 2006

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Dec 13, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in the United States of America (USA). This trial aims for a comparison of the safety and efficacy in subjects with type 2 diabetes using either self titration or physician guided titration according to the local standard of care.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 2

Interventions

  • insulin detemirDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Comparison of the change from baseline to end of treatmentTime frame: after 26 weeks in the value of laboratory-measured HbA1c between the self adjustment versus the standard of care group

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Plainsboro, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.